Stimulation/pSTAT | CD4+ T cells | NK cells | Monocytes |
---|
Bari (nM) | Upa (nM) | Tofa (nM) | Bari (nM) | Upa (nM) | Tofa (nM) | Bari (nM) | Upa (nM) | Tofa (nM) |
---|
JAK1/3-dependent cytokines |
IL-2/pSTAT5 | 29 | 10** | 11*** | 44 | 27* | 15*** | NS |
IL-4/pSTAT6 | 48 | 18*** | 18*** | 22 | 8* | 8*** | 45 | 22** | 35* |
IL-15/pSTAT5 | 40 | 17*** | 15*** | 67 | 40* | 22*** | NS |
IL-21/pSTAT3 | 64 | 20*** | 22*** | 62 | 24** | 21*** | 85 | 34 | 37 |
JAK2/2- or JAK2/TYK2-dependent cytokines |
IL-3/pSTAT5 | NS | NS | 26 | 12* | 102*** |
G-CSF/pSTAT3 | NS | NS | 65 | 84 | 97** |
GM-CSF/pSTAT5 | NS | NS | 30 | 13*** | 97*** |
JAK1/JAK2/TYK2-dependent cytokines |
IL-6/pSTAT3 | 61 | 58 | 56 | NS | 48 | 43 | 40 |
IL-10/pSTAT3 | 68 | 87 | 55 | 87 | 124 | 74 | 142 | 80*** | 104* |
IFN-γ/pSTAT1 | NS | NS | 38 | 30 | 46*** |
IFN-α/pSTAT1 | 64 | 40 | 132*** | 76 | 69 | 121*** | 97 | 44** | 163*** |
IFN-α/pSTAT3 | 27 | 17 | 51*** | NS | 14 | 6* | 23*** |
IFN-α/pSTAT5 | 23 | 14 | 36** | NS | 13 | 5** | 22*** |
- Reported IC50 values are least squares estimates of mixed models as described in the “Statistical analysis” section. For G-CSF, IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-15, and IL-21, reported IC50 values are based on two batches of data amounting to 12 donors for baricitinib and 6 donors for upadacitinib and tofacitinib; for GM-CSF, IFN-α, and IL-3, reported IC50 values are based on three batches of data amounting to 10 donors for baricitinib, 6 donors for upadacitinib, and 4 donors for tofacitinib. The primary pSTAT observed for each stimulus is reported in the table. Protein binding was not accounted for in the IC50 calculations
- *p < 0.01, **p < 0.001, ***p < 0.0001 compared to baricitinib
- Bari baricitinib, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte-macrophage colony-stimulating factor, IC50 half maximum inhibitory concentration, IFN interferon, IL interleukin, JAK Janus kinase, NK natural killer, NS no stimulation, pSTAT phosphorylated signal transducer and activator of transcription, Tofa tofacitinib, TYK tyrosine kinase, Upa upadacitinib